The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to ...

Objectives: To assess the efficacy and tolerability of valsartan and valsartan plus hydrochlorothiazide (HCTZ), given alone or as part of a combination regimen with other antihypertensive agents ...

For present purposes, the claims of the ‘659 Patent called for a pharmaceutical combination comprising valsartan and sacubitril “administered in combination” in about a 1:1 ratio.

In Honeywell International Inc. v. 3G Licensing, S.A., Appeal No. 23-1354, the Federal Circuit held that under the obviousness standard of 35 U.S.C.

The primary objective of PARADIGM-HF was to determine whether Entresto, a combination of sacubitril and a RAS inhibitor (valsartan), was superior to a RAS inhibitor (enalapril) alone in reducing ...

Sacubitril has recently been approved as part of the combination formulation sacubitril/valsartan (Entresto, Novartis). Endothelin also promotes remodeling and vasoconstriction; however ...

Global pharma major Lupin Limited (Lupin) announced that it has received United States Food and Drug Administration (FDA) approval for its Abbreviated new Drug Application (ANDA), sacubitril and ...

The patent in question (No. 8,101,659) covers the combination of sacubitril with valsartan and includes an extension awarded in return for carrying out studies of the drug in paediatric populations.

A Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help them mitigate the risk of ...

said the U.S. Court of Appeals for the Federal Circuit has upheld the company's U.S. combination patent for its blockbuster cardiac drug Entresto, also known as sacubitril/valsartan. The Swiss ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...